Glioblastoma
Conditions
Brief summary
Progression free survival (PFS), measured as the proportion of patients without progression of disease at three months from leukapheresis, Proportion of patients experienced grade 3 or higher adverse events related to the study treatment
Detailed description
Evaluation of the prognostic role of a positive DTH test after at least four vaccine administrations, Overall survival (OS), Ability to enhance the proportion of circulating immune effectors specific for tumor antigens; evaluation of the persistence of an anti-tumor immune response; determination of plasma levels of a panel of inflammatory cytokines and proangiogenic factors; evaluation of the prognostic and predictive role of tumor antigen expression in tumor tissue; analysis of the prognostic and predictive role of immune cells in the peripheral blood and in the tumor microenvironment
Interventions
Sponsors
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival (PFS), measured as the proportion of patients without progression of disease at three months from leukapheresis, Proportion of patients experienced grade 3 or higher adverse events related to the study treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the prognostic role of a positive DTH test after at least four vaccine administrations, Overall survival (OS), Ability to enhance the proportion of circulating immune effectors specific for tumor antigens; evaluation of the persistence of an anti-tumor immune response; determination of plasma levels of a panel of inflammatory cytokines and proangiogenic factors; evaluation of the prognostic and predictive role of tumor antigen expression in tumor tissue; analysis of the prognostic and predictive role of immune cells in the peripheral blood and in the tumor microenvironment | — |
Countries
Italy
Outcome results
None listed